FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C	20549	
vasiiiigtoii,	D.C.	20349	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL								
6	OMB Number: 3235-0287								
E	Estimated average burden								
II н	nours ner resnonse	. 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kane Erin N				2. Issuer Name and Ticker or Trading Symbol Chemours Co [CC]								ationship of Reporting all applicable) Director		Person(s) to Issu 10% Ov				
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/29/2023						Officer (g below)	give title		Other (s below)	pecify			
C/O THE	E CHEMO	URS COMPANY		-	4. If Am	endment, D	Date of	f Original Fi	iled (Month/Da	y/Year)			vidual or Joi	nt/Group	Filing (Check Appl	icable
1007 MA	RKET ST	REET									Line)	ne) X Form filed by One Reporting Person						
(Street)															,	•	One Reporti	ng
l ` ′	IGTON I	DE .	19801											Person				
					Rule	10b5-1	L(c)	Transa	ctic	n Indi	ication	1						
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						satisfy							
		Ta	able I - Non	-Deriva	tive S	ecuritie	s Ac	quired, I	Disp	osed o	of, or B	ene	ficially	Owned				
Date			2. Transac Date (Month/Da	Execution Date,		, Transaction Dispose Code (Instr.		rities Acquired (A) or ed Of (D) (Instr. 3, 4 an			5. Amount Securities Beneficiall Following	ly Owned (D) o Reported (I) (In		Direct Indirect Itstr. 4)	7. Nature of ndirect Beneficial Ownership			
							Code	v	Amount	(A) (D)	or	Price	Transaction (Instr. 3 and	nstr. 3 and 4)			Instr. 4)	
Common Stock								39,241.5741(1)			D							
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, if any		Code	s. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amor Securities Under Derivative Secur (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares			(Instr. 4)			
Stock Units	(2)	09/29/2023		A		891.2656		(3)		(3)	Common Stock	89	91.2656	\$28.05	9,392.1	509	D	

Explanation of Responses:

- 1. Includes stock units and dividend equivalent units.
- 2. Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock.
- 3. Payable in the second calendar year following separation of service.

Remarks:

Power of Attorney attached as Exhibit 24.

/s/ Nicole Perez Lengel, Attorney-in-Fact

10/03/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all persons by these presents, that the undersigned hereby constitutes and appoints Kristine Wellman and Nicole Perez Lengel of The Chemours Company, a Delaware corporation (the "Company"), and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in any such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July, 2023.

/s/ Erin N. Kane

Erin N. Kane